T-cell immunotherapy for adenoviral infections of stem-cell transplant recipients
T-cell immunotherapy for adenoviral infections of stem-cell transplant recipients
复制标题
DOI：
10.1196/annals.1358.013
复制
发表时间：
2005-01-01
期刊：
影响因子：
--
通讯作者：
Rooney, CM
中科院分区：
文献类型：
--
作者：
Leen, AM;Myers, GD;Rooney, CM
人腺病毒是普遍存在的裂解DNA病毒，可分为51种不同的血清型，根据基因组大小、组成、同源性和组织从A到F进行分组。腺病毒感染虽然频繁，但由于强大的先天和获得性免疫反应，在免疫能力强的人中很少是致命的。相比之下，腺病毒是免疫抑制患者发病和死亡的重要原因，对他们来说，治疗选择有限。由于抗病毒药物对重症腺病毒病的治疗效果不同，用体外扩增的病毒特异性细胞毒性T淋巴细胞(CTL)进行医源性重建是一种有吸引力的预防和治疗选择，特别是因为内源性恢复腺病毒特异性T细胞已被证明对控制体内感染具有重要意义。因此，我们在体外确定了人类T细胞对腺病毒的反应，并探索了过继T细胞免疫疗法作为预防或治疗移植后腺病毒感染的策略的潜力。
Human adenoviruses are ubiquitous lytic DNA viruses that can be divided into 51 different serotypes, grouped from A to F on the basis of genome size, composition, homology, and organization. Adenovirus infections, although frequent, are rarely fatal in immunocompetent individuals, due to potent innate and adaptive immune responses. By contrast, adenoviruses are a significant cause of morbidity and mortality in immunosuppressed individuals, for whom there are limited treatment options. Since antiviral drugs have variable efficacy in the treatment of severe adenovirus disease, iatrogenic reconstitution with in vitro expanded virus-specific cytotoxic T lymphocytes (CTLs) is an attractive option for prophylaxis and treatment, particularly because the endogenous recovery of adenovirus-specific T cells has proved important in controlling infection in vivo. Thus, we have characterized human T-cell responses to adenovirus in vitro and explored the potential of adoptive T-cell immunotherapy as a prophylactic or therapeutic strategy for adenovirus infections posttransplant.